The AMERICAN JOURNAL ON ADDICTIONS, published by WILEY, stands as a premier publication within the realms of Clinical Psychology, Medicine, and Psychiatry. With its ISSN 1055-0496 and E-ISSN 1521-0391, the journal has been a critical resource since its inception in 1992, consistently evolving to encompass a wide scope of addiction research and its implications on public health. Renowned for its rigorous peer-reviewed articles, it boasts impressive rankings, including Q1 status in both Clinical Psychology and Medicine (miscellaneous) for 2023, and a respectable Q2 in Psychiatry and Mental Health. As a foundational platform for disseminating cutting-edge research, the journal aims to facilitate the exchange of knowledge among researchers, healthcare professionals, and educators alike. Its significant impact on the academic community is underscored by its Scopus rankings—placing it in the top 26% of Clinical Psychology journals and the top 28% in Medicine (miscellaneous). By fostering an understanding of addiction and its treatments, the AMERICAN JOURNAL ON ADDICTIONS plays an essential role in guiding innovative practices and shaping future policies within the field.

ADDICTIVE BEHAVIORS is a prestigious journal published by PERGAMON-ELSEVIER SCIENCE LTD, specializing in the critical examination and exploration of addiction-related issues across diverse fields including Clinical Psychology, Psychiatry and Mental Health, and Toxicology. With a robust history dating back to 1975 and convergence extending to 2024, the journal is esteemed for its rigorous peer-reviewed research that contributes significantly to understanding addiction phenomena. Ranked in the Q1 category for its focus areas, it stands out within the academic community, evidenced by its impressive Scopus rankings—25th in Clinical Psychology and 14th in Toxicology—placing it in the top tier of its disciplines. This journal offers valuable insights into addiction behaviors, treatment methodologies, and public health implications, making it an essential resource for researchers, practitioners, and students seeking to advance their knowledge and impact the field. Although not Open Access, it provides vital access options for institutions and individuals invested in addiction studies.

DRUG AND ALCOHOL REVIEW, published by Wiley, is a leading journal dedicated to advancing the scholarship in the fields of drug and alcohol research. Since its inception in 1989, this esteemed publication has provided a critical platform for the dissemination of innovative research findings, reviews, and theoretical papers, addressing pressing issues in substance use and addiction. With an impact factor that places it in the Q1 category in both Health (social science) and Medicine (miscellaneous), it ranks #78 out of 371 in the Scopus index for Health and #115 out of 398 in Medicine, reflecting its significant influence and high citation rates among scholars. The journal is committed to fostering a multidisciplinary approach, integrating perspectives from psychology, sociology, public health, and medicine, to inform policy and practice. Accessible to researchers and practitioners alike, *DRUG AND ALCOHOL REVIEW* serves as an essential resource for anyone invested in understanding and addressing the complexities of drug and alcohol use in society.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

The Journal of Substance Use is a vital resource for researchers, professionals, and students in the fields of health and social sciences, published by Taylor & Francis Inc.. With an ISSN of 1465-9891 and E-ISSN of 1475-9942, this journal has been at the forefront of substance use research since its inception in 1996 and continues to provide a platform for the dissemination of innovative findings and critical analysis up to the year 2024. Ranking in the Q3 category for both Health (Social Science) and Medicine (Miscellaneous) in the 2023 quartiles, the journal encapsulates a broad spectrum of issues related to substance use, including addiction, intervention strategies, and policy implications. Although not an open-access journal, it remains accessible to a wide audience. With its substantial role in enhancing understanding and addressing the multi-faceted challenges of substance use, the Journal of Substance Use is essential for all stakeholders aiming to contribute to research and practice in this crucial area.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

Drug and Alcohol Dependence is a premier journal published by Elsevier Ireland Ltd, dedicated to the rigorous exploration and analysis of substance use disorders, including drug and alcohol dependencies. With its established history since 1975 and a remarkable convergence of research extending to 2024, the journal holds a prestigious position within the academic community, evidenced by its Q1 ranking in multiple categories, including Pharmacology, Psychiatry and Mental Health, and Toxicology for 2023. It ranks impressively among its peers, underscored by Scopus rankings of #46, #99, and #27 in key fields related to medical pharmacology and toxicology. As a non-open access title, it caters to a global readership of researchers, professionals, and students, providing them with peer-reviewed insights into critical developments and innovative methodologies in the field. The journal’s commitment to advancing knowledge and understanding of drug and alcohol dependence is essential for addressing the global challenges posed by substance use, making it a valuable resource for all stakeholders in public health and clinical practice.

Canadian Journal of Addiction is a leading platform dedicated to advancing the understanding of addiction and its multifaceted impacts on individuals and society. Published by LIPPINCOTT WILLIAMS & WILKINS, this journal aims to foster rigorous research and discussion in the field of addiction studies, contributing significantly to the intersection of psychiatry and mental health. With its ISSN 2368-4720 and E-ISSN 2368-4739, the journal is indexed in Scopus and has been categorized in the Q3 quartile for 2023, reflecting its emerging influence amongst peers. The Canadian Journal of Addiction facilitates a vital exchange of ideas and findings, crucial for researchers, practitioners, and students alike, addressing pressing issues related to addiction through innovative studies and insightful reviews. Subscribers and readers benefit from the latest findings as they navigate through the dynamic landscape of addiction research, enriching both academic knowledge and practical applications.

The Journal of Addictions Nursing, published by Lippincott Williams & Wilkins, serves as a pivotal resource in the field of psychiatric and mental health nursing. With an ISSN of 1088-4602 and an E-ISSN of 1548-7148, this esteemed journal has been dedicated to advancing the knowledge and practice of addiction nursing since its inception in 1989. As of 2023, it ranks in the Q3 category of psychiatry and mental health, highlighting its significance amidst its peers. The journal provides a platform for the dissemination of original research, reviews, and clinical practices that address the complexities of addiction treatment and care. While it currently does not offer open access options, its valuable insights are accessible to practitioners and researchers committed to improving patient outcomes. With content spanning from 1989 to 2024, the journal continues to shape the discourse in this vital area of nursing, making it an essential read for professionals and scholars aiming to stay at the forefront of addiction nursing and intervention strategies.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.